GeneChem
VC Fund
Montréal, Canada
GeneChem is a VC fund in Montréal focused on Biotechnology and Medical. GeneChem fund and the changing landscape of the genomics industry, the principals set out to raise their second focused fund, GeneChem Therapeutics Venture Fund L.P.. With committed capital of $136.5 million, the Therapeutics Fund's objectives were to invest within the genomics industry but specifically in companies developing therapeutics forproliferative disorders including cancer, infectious diseases, inflammation and diabetes.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries GeneChem invests in
Stages GeneChem invests in
Countries GeneChem invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Fabienne Perreau
|
|||
Inès Holzbaur
|
|||
John Clement
|
|||
| See all 8 contacts → | |||
Investment Focus
Industry
- Biotechnology 11 (92%)
- Medical 5 (42%)
- Biopharma 4 (33%)
- Pharmaceutical 4 (33%)
- Health Care 2 (17%)
Stage
- Funding Round 4 (33%)
- Series B 3 (25%)
- Series A 2 (17%)
- Series D 1 (8%)
- Venture - Series Unknown 1 (8%)
Country
- United States 9 (75%)
- Canada 2 (17%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Elizabeth Douville
General Partner
|
General Partner | Total investments: 5 | Find email | |
Maxime Pesant
Vice-President, Finance
|
Vice-President, Finance | Total investments: 3 | Find email | |
|
Fabienne Perreau
Administrative Assistant
|
Administrative Assistant | Total investments: 0 | Find email | |
|
Inès Holzbaur
General Partner
|
General Partner | Total investments: 0 | Find email | |
|
John Clement
General Partner
|
General Partner | Total investments: 0 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Triad Life Sciences
|
Triad Life Sciences is a biotechnology company, specializing in the science of bioactive extracellular matrixes (ECM). Collectively housing over 100 years of experience in regenerative medicine technologies, Triad boasts a strong leadership team consisting of industry pioneers and experts. | $18.3M / Venture - Series Unknown / Aug 31, 2021 | |
Ambit Biosciences
|
Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit's lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3)inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit's clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon. | $49.3M / Series D / Nov 14, 2007 | |
Osprey Pharmaceuticals USA
|
Osprey Pharmaceuticals USA is a clinical stage company focused on the development of novel protein therapeutics for the treatment of inflammatory and immune diseases.The company is advancing a pipeline of proprietary fusion protein therapeutics known as Leukocyte Population Modulators (LPMs) that are designed to selectively target andneutralize chemokine-activated leukocytes underlying a variety of inflammatory and immune diseases.The Company’s lead candidate, CCL2-LPM targeting the CCR2 chemokine receptor expressed by certain pathologically activated leukocytes is in a Phase Ib clinical trial for the treatment of IgA nephropathy. | $9M / Jan 30, 2007 | |
Xanthus Pharmaceuticals
|
Xanthus Pharmaceuticals Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, acquisition, and commercialization of small-molecule therapeutics for the treatment of cancer and autoimmune disorders. | $25M / Series B / Dec 01, 2006 | |
|
Xanthus Pharmaceuticals
|
Xanthus Pharmaceuticals Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, acquisition, and commercialization of small-molecule therapeutics for the treatment of cancer and autoimmune disorders. | $30.8M / Series B / Dec 12, 2003 | |
Idun Pharmaceuticals
|
IDUN Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of human therapeutics to control apoptosis. Its products under Phase 2 and preclinical trials include drugs for liver disease, CNS diseases, inflammation, and cancer, as well as IDN-6556 for the treatment of liver diseases in patients infected withHepatitis C virus. The company was founded in 1993 and is based in San Diego, California. As of July 30, 2010, IDUN Pharmaceuticals, Inc. operates as a subsidiary of Conatus Pharmaceuticals Inc. | Series A / Dec 09, 2002 | |
Salmedix
|
Salmedix is an oncology drug development company with a commercial focus on the treatment of hematologic malignancies, or blood cancers. Its primary product, SDX-105, is marketed by healthcare professionals in Germany for the treatment of several types of blood cancers.Salmedix conducts Phase II clinical trials for SDX-105 in the U.S. and Canada.Its other clinical-stage product candidates, SDX-101 and SDX-102, each with significant prior human clinical experience, are also in Phase II development.Founded in 2000 by David Kabakoff, Salmedix is headquartered in San Diego, California. | $27.5M / Series B / Jun 19, 2002 | |
GeneFormatics
|
GeneFormatics is a biotechnology company specializing in structural proteomics. | $22M / Oct 17, 2001 | |
Interomex BioPharmaceuticals
|
Interomex Biopharmaceuticals Inc. is dedicated to the identification of novel biological targets in key cellular processes with the aim of discovering lead compounds for the treatment of disease.The company’s proprietary Repressed Trans-activator (RTATM) technology can be used to detect protein-protein interactions between a host and aninfectious agent, as well as within cells in normal and diseased states. A particular advantage of RTATM is its ability to detect the interactions of transcription transactivator proteins, which are key control points in viral infections and cell activation. | $4M / Series B / Oct 05, 2001 | |
|
Viron Therapeutics
|
Viron Therapeutics is a Biotechnology company | $7.3M / Series A / Jan 19, 2000 | |
| See all 12 investments → | |||
Co-Investors
Gimv
3 deals together
Hambrecht & Quist Capital Management
3 deals together
ARCH Venture Partners
2 deals together
CDIB BioScience Ventures
2 deals together
CDP Capital Technology Ventures
2 deals together
China Development Industrial Bank (CDIB)
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does GeneChem invest in?
GeneChem invests primarily in Biotechnology, Medical and Biopharma startups, most often at Funding Round and Series B stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact GeneChem?
Public channels for GeneChem include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at GeneChem?
The team at GeneChem includes Elizabeth Douville (General Partner), Maxime Pesant (Vice-President, Finance) and Fabienne Perreau (Administrative Assistant), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
